Reports Q4 revenue $164..3M, consensus $155.03M. The company said, “Our performance in 2023 underscores our strong execution, with combined full year 2023 net sales of $259.8 million for our growth products, Qelbree and GOCOVRI, which far exceeded the decline in net sales of Trokendi XR. Furthermore, that represents 57% growth compared to full year 2022. Qelbree delivered robust growth of 91% in prescriptions and benefited from a much improved gross-to-net adjustment resulting in 129%, growth in net sales. In 2024, we look forward to continued growth across our key growth products and the launch of SPN-830 in the second half of 2024 as we complete the transition from our legacy products to our growth products. In addition, in 2024 we anticipate several exciting clinical milestones as we progress our pipeline of novel product candidates.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SUPN:
- Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
- Supernus Pharmaceuticals (SUPN) Q4 Earnings Cheat Sheet
- Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
- Supernus Pharmaceuticals Wins Patent Infringement Lawsuit
- Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
